Search

Displaying results 2321 - 2330 of 2674 in total
  1. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L10145] The FDA approved Selinexor in June 2019.

  2. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression

  3. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age. … [L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment

  4. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263506] It was subsequently approved by the FDA in March 2024.[L50386]

  5. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC.

  6. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  7. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are

  8. Drug

    Von Willebrand factor human

    go.drugbank.com/drugs/DB13133
    ApprovedInvestigational

    It was first approved by the FDA in 2015.

  9. Drug

    Alginic acid

    go.drugbank.com/drugs/DB13518
    ApprovedInvestigationalWithdrawn

    Alginic acid is an FDA-approved food ingredient in soup and soup mixes as an emulsifier, thickener, and stabilizer [L2693].

  10. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [L30598] An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 [L42645] and was fully approved